Matthew Winton is COO of Inozyme Pharma, Inc.. Currently has a direct ownership of 4,898 shares of INZY, which is worth approximately $14,645. The most recent transaction as insider was on Sep 30, 2024, when has been sold 1,710 shares (Common Stock) at a price of $4.45 per share, resulting in proceeds of $7,609. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.9K
53.64% 3M change
n/a 12M change
Total Value Held $14,645

Matthew Winton Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 30 2024
BUY
Grant, award, or other acquisition
$7,609 $4.45 p/Share
1,710 Added 25.88%
4,898 Common Stock
Mar 28 2024
BUY
Grant, award, or other acquisition
$10,616 $3.33 p/Share
3,188 Added 50.0%
3,188 Common Stock
MW

Matthew Winton

COO
Boston, MA

Track Institutional and Insider Activities on INZY

Follow Inozyme Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells INZY shares.

Notify only if

Insider Trading

Get notified when an Inozyme Pharma, Inc. insider buys or sells INZY shares.

Notify only if

News

Receive news related to Inozyme Pharma, Inc.

Track Activities on INZY